Private Wealth Partners LLC raised its stake in shares of GenMark Diagnostics, Inc (NASDAQ:GNMK) by 23.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 370,000 shares of the medical equipment provider’s stock after purchasing an additional 70,000 shares during the quarter. Private Wealth Partners LLC owned about 0.66% of GenMark Diagnostics worth $2,361,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of GNMK. Millennium Management LLC increased its stake in GenMark Diagnostics by 1,118.6% during the 2nd quarter. Millennium Management LLC now owns 741,752 shares of the medical equipment provider’s stock valued at $4,732,000 after purchasing an additional 680,882 shares in the last quarter. Bellevue Group AG increased its stake in GenMark Diagnostics by 53.4% during the 1st quarter. Bellevue Group AG now owns 1,186,502 shares of the medical equipment provider’s stock valued at $6,455,000 after purchasing an additional 412,825 shares in the last quarter. BlackRock Inc. increased its stake in GenMark Diagnostics by 8.1% during the 2nd quarter. BlackRock Inc. now owns 3,358,717 shares of the medical equipment provider’s stock valued at $21,429,000 after purchasing an additional 250,306 shares in the last quarter. JPMorgan Chase & Co. increased its stake in GenMark Diagnostics by 2.8% during the 1st quarter. JPMorgan Chase & Co. now owns 4,904,257 shares of the medical equipment provider’s stock valued at $26,679,000 after purchasing an additional 131,504 shares in the last quarter. Finally, Bradley Foster & Sargent Inc. CT acquired a new stake in shares of GenMark Diagnostics in the second quarter worth $651,000. Institutional investors and hedge funds own 99.47% of the company’s stock.

In related news, CEO Hany Massarany sold 6,203 shares of the stock in a transaction on Friday, August 24th. The shares were sold at an average price of $7.16, for a total transaction of $44,413.48. Following the sale, the chief executive officer now directly owns 682,491 shares of the company’s stock, valued at $4,886,635.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 20,230 shares of company stock worth $147,242 over the last three months. 7.09% of the stock is currently owned by insiders.

GNMK has been the topic of a number of research reports. BidaskClub upgraded shares of GenMark Diagnostics from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 1st. Canaccord Genuity increased their price objective on shares of GenMark Diagnostics from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Friday, June 29th. Zacks Investment Research lowered shares of GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 18th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of GenMark Diagnostics in a research note on Tuesday, July 31st. Finally, ValuEngine upgraded shares of GenMark Diagnostics from a “strong sell” rating to a “sell” rating in a research note on Friday, August 10th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $11.00.

NASDAQ:GNMK opened at $7.54 on Tuesday. The firm has a market capitalization of $441.01 million, a PE ratio of -6.23 and a beta of 0.88. GenMark Diagnostics, Inc has a 1-year low of $3.63 and a 1-year high of $9.93. The company has a current ratio of 2.04, a quick ratio of 1.80 and a debt-to-equity ratio of 0.19.

GenMark Diagnostics (NASDAQ:GNMK) last released its quarterly earnings data on Monday, July 30th. The medical equipment provider reported ($0.30) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.09). The business had revenue of $14.94 million during the quarter, compared to analyst estimates of $14.74 million. GenMark Diagnostics had a negative return on equity of 87.96% and a negative net margin of 91.58%. research analysts predict that GenMark Diagnostics, Inc will post -0.85 EPS for the current fiscal year.

GenMark Diagnostics Profile

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

Read More: Leveraged Buyout (LBO) Explained

Want to see what other hedge funds are holding GNMK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GenMark Diagnostics, Inc (NASDAQ:GNMK).

Institutional Ownership by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.